Month: September 2020

HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) — Recruiter.com Group, Inc. (OTCQB: RCRT) (“Recruiter.com”), a leading online hiring platform using A.I. and machine learning to connect its network of over 26,000 small and independent recruiters with employers, has announced that they have entered engagements with three new clients in the fast-growing mortgage and digital lending industry. Recruiter.com believes that these new clients could potentially generate more than $13 million of revenue over the next eighteen months.“We are pleased to project multi-million-dollar revenue opportunities with our initial set of mortgage clients,” said Evan Sohn, CEO of Recruiter.com. “We believe our approach to recruiting talent faster with technology has proven highly effective within the mortgage space. We look forward...

SAMPO PLC                 MANAGERS’ TRANSACTIONS   15 September 2020 at 3:15 pmCORRECTION: Sampo plc: Managers’ Transactions (Lapveteläinen)Correction to Sampo plc’s (business code 0142213-3) stock exchange release regarding Managers’ Transactions on 10 August 2020 at 2:40 pm. Due to the company’s technical error, the volume and average price were different than in the notification by the notifier to the company. Below is the correct notification.____________________________________________Person subject to the notification requirementName: Leviathan OyPosition: Closely associated person(X) Legal person(1): Person Discharging Managerial Responsibilities In IssuerName: Patrick LapveteläinenPosition: Other senior managerIssuer: Sampo plcLEI: 743700UF3RL386WIDA22Notification type: AMENDMENTReference number: 743700UF3RL386WIDA22_20200810135144_2Amendment...

SAMPO OYJ                             JOHDON LIIKETOIMET  15.9.2020 klo 15.15KORJAUS: Sampo Oyj: Johdon liiketoimet (Lapveteläinen)Korjaus Sampo Oyj:n (Y-tunnus 0142213-3) 10.8.2020 klo 14.40 julkaisemaan pörssitiedotteeseen koskien johdon liiketoimia. Yhtiön teknisestä virheestä johtuen volyymi ja keskihinta ilmoitettu ilmoitusvelvollisen yhtiölle tekemästä ilmoituksesta poikkeavalla tavalla. Alla korjattu ilmoitus.____________________________________________IlmoitusvelvollinenNimi: Leviathan OyAsema: Lähipiiriin kuuluva henkilö(X) Oikeushenkilö(1): Liikkeeseenlaskijassa johtotehtävissä toimiva henkilö Nimi: Patrick LapveteläinenAsema: Muu ylin johtoLiikkeeseenlaskija: Sampo OyjLEI: 743700UF3RL386WIDA22Ilmoituksen luonne: MUUTOSViitenumero: 743700UF3RL386WIDA22_20200810135144_2Muutoksen selostus:Yhtiön teknisestä virheestä johtuen volyymi...

TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) — Cartier Iron Corporation (CSE: CFE) (“Cartier Iron” or the “Company”), is pleased to announce that due to an oversubscription on its previously announced (see Cartier Iron news releases dated September 2, 8 and 10, 2020) non-brokered private placement (the “Private Placement”) it is increasing the aggregate size of the offering from 18 million units to 18.5 million units of Cartier Iron at a price of $0.07 per unit (“Units”) for aggregate proceeds of $1,295,000. On September 10, 2020, the Company closed a first tranche of 7,142,858 Units for proceeds of $500,000 and it expects to close the remaining portion of the financing on September 17, 2020.Each of the Units consists of one common share in the capital of Cartier Iron (a “Common Share”) and one Common Share purchase warrant (a “Warrant”)....

Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP). The FDA provided positive feedback supporting Equillium’s clinical development plans for evaluating itolizumab (EQ001) as a potential treatment for hospitalized patients with COVID-19. With this feedback, Equillium plans on finalizing the protocol and anticipates submitting its U.S. IND application to the FDA in October 2020 in...

TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to provide a comprehensive update on its adult-use market initiatives to expand the market presence and share of its Color Cannabis and Saturday brands across Canada.With the exclusive launch of renowned strain Black Sugar Rose, the introduction of a vaporization (vape) and pre-roll line, as well as new nitrogen-infused packaging, the Company is executing on its commercial growth plans.“Since the beginning of the year, we’ve made great strides in accelerating our product innovation, further enhancing the market appeal of our Color and Saturday Cannabis brands, as well as expanding distribution to a discerning national consumer base...

TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) — Cardinal Resources Limited (ASX/TSX: CDV) (“Cardinal” or “Company”) advises that in accordance with their publicly stated acceptance intention, the Cardinal Directors who collectively hold approximately 6.07% of Cardinal’s ordinary shares (Cardinal Shares) have each instructed their broker / controlling participant to initiate acceptance of the off-market takeover offer by Shandong Gold Mining (HongKong) Co., Ltd (“Shandong Gold Offer”) in respect of all of the Cardinal Shares they own or control. The Shandong Gold Offer remains subject to a number of standard market conditions for a transaction of this nature (including primarily, 50.1% minimum acceptance by Cardinal Shareholders) as set out in the in the Bidder’s Statement.  For further information in relation to the Shandong Gold Offer,...

VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) — Gold Bull Resources Corp. (TSX-V: GBRC) (“Gold Bull” or the “Company”) is pleased to announce it has appointed its US based management and technical team.Gold Bull Chairman Craig Parry commented, “We are thrilled to have attracted this high calibre technical team who have an impressive track records of  making discoveries. I’m looking forward working with such a great pool of talent as we continue to assess and evaluate future acquisitions for the Company.”As Chief Geophysicist at Independence Group, David led regional and in-mine geophysics teams to exploration success, including discovery of the Moran and Long North nickel orebodies at Kambalda and the Rosie nickel deposit in the Duketon greenstone belt in Western Australia.  David also discovered The Horn nickel sulphide...

– Formal notice confirms intent to grant patent for pharmaceutical tetracycline compositions for dermatological use –WOODCLIFF LAKE, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application covering its pharmaceutical tetracycline (including minocycline) compositions for dermatological use (U.S. Patent Application No.: 16/514,459).“The notice of allowance from the USPTO further protects our dermatology portfolio,” said John Koconis, Chief Executive...

EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview on Thursday, September 17, 2020 at 8:00 a.m. ET during the Cantor Virtual Global Healthcare Conference.A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.About Gritstone Oncology Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies...